11.2 Capital

11.2 Capital is a San Francisco-based early-stage venture capital firm built around a simple but demanding idea: technical founders need enough momentum to escape conventional limits. Founded in 2014 by Shelley Zhuang, the firm backs entrepreneurs working on scientific and engineering problems that often take longer to validate but can create much larger category shifts when they succeed.

The firm's name references Earth's escape velocity of 11.2 kilometers per second. That is not just clever branding. It is a useful shorthand for how 11.2 Capital evaluates venture opportunities: look for founders, markets, and technologies with enough force to break away from incremental software cycles and build something more durable.

About 11.2 Capital

11.2 Capital focuses on early-stage companies building breakthrough technology with global ambitions. The firm is not trying to be a generic capital provider for whatever category happens to be the loudest in a given quarter. Its sharper identity centers on research-driven innovation, technical diligence, and companies where engineering depth is part of the moat.

Founder and Managing Partner Shelley Zhuang brings a technical background to that strategy, including computer science research, venture investing, and company-building experience. The research identifies Partner David Dorsey and Principals Jake Smith and Pramod Gosavi as members of the investment team. Together, that group gives 11.2 Capital a venture practice built around understanding engineering depth alongside market opportunity.

Investment Philosophy

Deep technology rarely follows predictable timelines. Scientific discovery, advanced engineering, and infrastructure innovation often require years of development before they reach commercial scale, so the strongest investors in this category need patience long before consensus arrives. 11.2 Capital has positioned itself around that reality by backing founders whose work can look technically difficult before it looks commercially obvious.

The firm appears most interested in businesses with meaningful intellectual property, defensible research, and the potential to create new market opportunities. That philosophy matters because many of the markets 11.2 Capital studies are not won by distribution alone. They reward technical depth, credible founder insight, and investors willing to understand hard problems before the broader market catches up.

Market Focus and Thesis

11.2 Capital invests primarily at the early stage across sectors where technical expertise can create a durable competitive advantage. Its focus areas include artificial intelligence, enterprise software, cybersecurity, robotics, quantum technologies, space technology, therapeutics, climate technology, and data-driven health.

Those categories are different on the surface, but they share the same venture question: can a technical team turn difficult science or engineering into a company that changes how a market works? That is where specialist investors can matter. They are not just underwriting current traction. They are evaluating feasibility, timing, founder capability, and whether the technical insight can become a real business.

Portfolio and Ecosystem Positioning

The firm's representative portfolio shows exposure to advanced engineering, software infrastructure, healthcare, and frontier science. Companies associated with the 11.2 Capital portfolio include Cruise, Ginkgo Bioworks, Hinge Health, Anyscale, Coalesce, Orbital Sidekick, Hubble Network, Kolena, Permiso, Sardine, uMed, TigerGraph, Deep Genomics, and Avaamo.

Viewed together, those companies look less like a random collection of startup logos and more like a thesis map. They span autonomous systems, synthetic biology, digital health, AI infrastructure, cybersecurity, enterprise data platforms, satellite technology, healthcare research, and advanced analytics. The pattern is not one technology cycle. It is a long-running bet that foundational technical platforms can reshape multiple industries over time.

Leadership and Partners

Leadership is especially important for a venture firm whose strategy depends on technical judgment. Zhuang's background gives 11.2 Capital a founder-facing narrative that differs from a purely financial lens. The firm can speak to research intensity, product complexity, and the long path from technical breakthrough to commercial adoption.

Dorsey, Smith, and Gosavi add to that operating picture by supporting the firm's sourcing, evaluation, and portfolio work. For founders, that matters because deep-tech startups often need investors who understand both the science and the company-building grind. The right partner has to help with capital, but also with timing, hiring, syndicate formation, and the translation of technical credibility into market trust.

Why Founders Pay Attention

For founders building highly technical companies, investor alignment can matter as much as the check size. A deep-tech startup may need years of iteration before the market fully understands what the team has built, and that requires investors who do not panic when progress looks different from a typical SaaS growth curve.

11.2 Capital's investment history suggests an emphasis on that kind of alignment. Rather than treating complexity as a reason to avoid a company, the firm treats it as a place where durable advantages may be forming. That positioning can make 11.2 Capital relevant for founders working in AI, healthcare, infrastructure software, robotics, cybersecurity, quantum technologies, climate technology, and space.

What This Signals for Venture Capital

The broader venture market is becoming more technically demanding. AI infrastructure, advanced healthcare platforms, cybersecurity, climate innovation, robotics, and next-generation computing all require investors who can evaluate more than customer acquisition metrics and short-term revenue curves. The underwriting question is increasingly about whether a technical breakthrough can become a scalable company.

That is why specialized venture firms are gaining importance. Generalist capital can still help companies scale, but early conviction in difficult technical markets often comes from investors willing to study the details before the category has obvious momentum. 11.2 Capital sits in that lane, backing founders where scientific and engineering complexity are central to the opportunity.

The Bigger Industry Shift

Many of tomorrow's defining companies will come from research laboratories, engineering organizations, healthcare institutions, and advanced computing environments rather than purely consumer software ecosystems. As those markets mature, investors who can understand difficult technical problems will play a larger role in helping founders turn breakthrough ideas into enduring businesses.

11.2 Capital's approach reflects that shift. By maintaining a consistent focus on technical founders across artificial intelligence, enterprise software, cybersecurity, robotics, quantum technologies, space technology, therapeutics, climate technology, and data-driven health, the firm has built a clear place in the venture market: a partner for entrepreneurs pursuing ambitious solutions to complex global problems.